<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-159609</identifier>
<setSpec>1699-695X</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">No disponible</dc:title>
<dc:description xml:lang="en">Methotrexate has been widely used for many years in the treatment of a variety of diseases. Low-dose oral methotrexate therapy has gained wide acceptance for its use in rheumatoid arthritis because of its efficacy and tolerability. The toxicity of methotrexate is the main reason for cessation of treatment. Gastrointestinal complications are the most common adverse effects of low-dose oral methotrexate therapy, followed by stomatitis, hepatotoxicity, skin rash, hair loss, pulmonary and haematological toxicity, although pancytopenia is a rare adverse effect of low-dose oral methotrexate therapy. The most important risk factor for methotrexate toxicity is impaired renal function (AU)</dc:description>
<dc:creator>Romero Candel, Gregorio</dc:creator>
<dc:creator>Igualada Quintanilla, Jesús</dc:creator>
<dc:creator>Tejada Cifuentes, Francisco</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Metotrexato ha sido durante años ampliamente utilizado para el tratamiento de diversas enfermedades. El tratamiento con bajas dosis de metotrexato oral ha alcanzado gran aceptación para su uso en la artritis reumatoide debido a su eficacia y tolerabilidad. La toxicidad del metotrexato es la causa principal para la interrupción del tratamiento. Las complicaciones gastrointestinales son los efectos adversos más comunes del tratamiento con metotrexato oral a bajas dosis, seguido de la estomatitis, hepatotoxicidad, erupción cutánea, pérdida de cabello, toxicidad pulmonar y hematológica, aunque la pancitopenia es un efecto adverso raro de la terapia oral con bajas dosis. El factor de riesgo más importante para la toxicidad de metotrexato es la disminución de la función renal (AU)</dc:description>
<dc:source>Rev. clín. med. fam;9(3): 159-166, oct. 2016. tab</dc:source>
<dc:identifier>ibc-159609</dc:identifier>
<dc:title xml:lang="es">Metotrexato: toxicidad pulmonar, hepática y hematológica</dc:title>
<dc:subject>^d4421^s22012</dc:subject>
<dc:subject>^d28612</dc:subject>
<dc:subject>^d5175^s22012</dc:subject>
<dc:subject>^d10385^s22012</dc:subject>
<dc:subject>^d31333^s22036</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d28169^s22020</dc:subject>
<dc:subject>^d31333^s22012</dc:subject>
<dc:subject>^d28169^s22000</dc:subject>
<dc:subject>^d7851^s22036</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d13668^s22012</dc:subject>
<dc:subject>^d6063^s22021</dc:subject>
<dc:subject>^d28169^s22073</dc:subject>
<dc:subject>^d1178^s22057</dc:subject>
<dc:subject>^d1178^s22012</dc:subject>
<dc:type>article</dc:type>
<dc:date>201610</dc:date>
</metadata>
</record>
</ibecs-document>
